Assessing the efficacy and safety for novel drug candidates for Alzheimer's disease requires a rigorous evaluation process. Preclinical studies typically involve in vitro and in vivo experiments to assess the potential ability in targeting disease-related pathways. Once promising candidates emerge, they enter clinical trials these are conducted in